Optimal Timing of BR55 CEUS of the Ovaries
An Exploratory Study to Determine the Optimal Timing of BR55 Contrast Enhanced Ultrasound (CEUS) of the Ovaries in Pre-menopausal Women
Sponsor: Bracco Diagnostics, Inc
Terminated
Sponsor decision; expiration of available study agent due to long recruitment timeline.
Other terminated trials from Bracco Diagnostics, Inc
- Colorectal Cancer · May 2025
- Bowel Ischemic · Phase PHASE3 · May 2024
- Hypothyroidism · Phase PHASE4 · Mar 2022
- Pancreatic Ductal Adenocarcinoma · Phase PHASE2 · Jul 2021
- Ovarian Cancer · Phase PHASE2 · Jul 2021
More terminations from Bracco Diagnostics, Inc
This PHASE2 trial investigates Ovarian Cancer and is currently terminated or withdrawn. Bracco Diagnostics, Inc leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Completed → Active Not Recruiting
-
Apr 2022 — Sep 2023 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Mar 2021 — Apr 2022 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bracco Diagnostics, Inc
- National Institutes of Health (NIH)
For direct contact, visit the study record on ClinicalTrials.gov .